PMC8481915_01
Ex vivo drug screening in metastatic parotid duct carcinoma. (A) Schematic presentation of the study strategy. (B) Gallery view of representative 20x immunofluorescence microscopy images of the sample cells treated for 96 h with the indicated drugs in five different concentrations (nM). KRT19 staining shown in red and VIM staining in green. Bars: 50 microm. (C) Scatter plot showing correlation of the mean GR score of 125 drugs in five doses for the KRT19+ and VIM+ cells. (D) EGFR-TKis were identified as drugs with a selective cytotoxic effect on the KRT19+ cells. Box plots showing the GR scores for the five doses of all EGFR-TKi included in the screen and compared using paired Student's t-test.
fonc-11-735820-g001.jpg
PMC8481915_01_fonc-11-735820-g001.jpg
f1
The ex vivo drug screening data (Supplementary Figures S1-S3) are deposited to Mendeley data (DOI: ).
Validation of HER2 status and targeted therapy. (A) Immunohistochemistry validation of HER2 staining in the affected lymph node. Scale bars: 2.5 mm, 250 microm, and 100 microm (left to right). (B) Radiologic response of patient. Left, prior to treatment, and right, after four cycles of treatment with T-DM1.
fonc-11-735820-g002.jpg
PMC8481915_01_fonc-11-735820-g002.jpg
f2
The ex vivo drug screening data (Supplementary Figures S1-S3) are deposited to Mendeley data (DOI: ).
Repeat ex vivo drug screen in recurrent disease. (A) Scatter plot showing correlation of the mean GR score of 193 drugs in five doses for the HER2+ and VIM+ cells. (B) Scatter plot showing correlation of the IC50 estimate of the analyzed drugs between the HER2+ sample B cells and KRT19+ sample A cells. (C) Box plots showing the GR scores for the five doses of afatinib, neratinib, erlotinib, and lapatinib in sample A and B KRT19+ and HER+ cells. Afatinib and neratinib displayed a statistically significant differential effect on the KRT19+ and HER+ cells from sample B as compared using paired Student's t-test. (D) Gallery view of representative 20x immunofluorescence microscopy images of the sample cells treated for 96 h with the different EGFR-TKis in five different concentrations (nM). KRT19 staining shown in blue, VIM staining in green and HER2 staining in red. Bars: 50 microm.
fonc-11-735820-g003.jpg
PMC8481915_01_fonc-11-735820-g003.jpg
f3
The ex vivo drug screening data (Supplementary Figures S1-S3) are deposited to Mendeley data (DOI: ).